MDT

88.32

-0.47%↓

VEEV

281.13

+0.19%↑

A

119.05

-1.94%↓

WBA

11.56

+0.43%↑

HQY

101.32

-1.8%↓

MDT

88.32

-0.47%↓

VEEV

281.13

+0.19%↑

A

119.05

-1.94%↓

WBA

11.56

+0.43%↑

HQY

101.32

-1.8%↓

MDT

88.32

-0.47%↓

VEEV

281.13

+0.19%↑

A

119.05

-1.94%↓

WBA

11.56

+0.43%↑

HQY

101.32

-1.8%↓

MDT

88.32

-0.47%↓

VEEV

281.13

+0.19%↑

A

119.05

-1.94%↓

WBA

11.56

+0.43%↑

HQY

101.32

-1.8%↓

MDT

88.32

-0.47%↓

VEEV

281.13

+0.19%↑

A

119.05

-1.94%↓

WBA

11.56

+0.43%↑

HQY

101.32

-1.8%↓

Search

Immunocore Holdings PLC ADR

Затворен

33.27 3.36

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

31.91

Максимум

33.29

Ключови измерители

By Trading Economics

Приходи

29M

5M

Продажби

9.8M

94M

Марж на печалбата

5.35

Служители

493

EBITDA

13M

-3.6M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+100.22% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

125M

1.6B

Предишно отваряне

29.91

Предишно затваряне

33.27

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Immunocore Holdings PLC ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.07.2025 г., 19:37 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

M3-Brigade Shares Fall on Merger With ReserveOne

8.07.2025 г., 23:45 ч. UTC

Пазарно говорене

Gold Edges Lower, Weighed by Higher Treasury Yields -- Market Talk

8.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Rise as Yen Weakens -- Market Talk

8.07.2025 г., 23:27 ч. UTC

Пазарно говорене

Australian REITs Yet to Offer Enough Appeal -- Market Talk

8.07.2025 г., 23:27 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.07.2025 г., 23:21 ч. UTC

Пазарно говорене

Summerset Bull Lauds Strong 2Q Sales Volumes -- Market Talk

8.07.2025 г., 23:21 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.07.2025 г., 22:29 ч. UTC

Придобивния, сливания и поглъщания

Capricorn to Pay A$1.5 Million in Cash and Shares

8.07.2025 г., 22:28 ч. UTC

Придобивния, сливания и поглъщания

Capricorn Metals Enters Binding Agreement to Buy Claw Gold Project

8.07.2025 г., 21:58 ч. UTC

Пазарно говорене

Kura Sushi Closely Watching U.S. Tariff Negotiations on Asian Goods -- Market Talk

8.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

8.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.07.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.07.2025 г., 19:53 ч. UTC

Пазарно говорене

Copper Posts Biggest One-Day Gain Ever to Hit Record on Tariff Chatter -- Market Talk

8.07.2025 г., 19:53 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

8.07.2025 г., 19:45 ч. UTC

Пазарно говорене

Canada Unlikely to Succeed in Bid for Tariff-Free Trade With U.S. -- Market Talk

8.07.2025 г., 19:29 ч. UTC

Пазарно говорене

U.S. Consumer-Credit Growth Slowed in May -- Market Talk

8.07.2025 г., 19:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Lower -- Market Talk

8.07.2025 г., 19:11 ч. UTC

Пазарно говорене

Bank of Canada's Rate Cuts Deliver Muted Relief Along the Curve -- Market Talk

8.07.2025 г., 19:01 ч. UTC

Пазарно говорене

Oil Futures Gain With Support From Products -- Market Talk

8.07.2025 г., 18:49 ч. UTC

Печалби

Hershey Names New CEO, Continuing Leadership Shuffle. The Stock Falls. -- Barrons.com

8.07.2025 г., 18:41 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Mixed in June -- Market Talk

8.07.2025 г., 18:38 ч. UTC

Пазарно говорене

Gold Falls as Markets Digest Details of Trump Tariffs -- Market Talk

8.07.2025 г., 18:23 ч. UTC

Пазарно говорене

Analysts Anticipate Lower Ethanol Inventories -- Market Talk

8.07.2025 г., 18:10 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

8.07.2025 г., 18:10 ч. UTC

Пазарно говорене

Freeport-McMoRan Jumps on Trump Tariff Plan for Copper Imports -- Market Talk

8.07.2025 г., 17:24 ч. UTC

Пазарно говорене

Election, Dollar Seen as Potential Headwinds for Ibovespa -- Market Talk

8.07.2025 г., 17:06 ч. UTC

Пазарно говорене

KeyCorp and Regional Banks Set for a Catchup -- Market Talk

8.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Immunocore Holdings PLC ADR Прогноза

Ценова цел

By TipRanks

100.22% нагоре

12-месечна прогноза

Среден 64.89 USD  100.22%

Висок 100 USD

Нисък 33 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Immunocore Holdings PLC ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

8

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

27.895 / 30.16Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.